Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of EMB-001 Formulations
NCT03404817Phase 1Completed
- Sponsor
- Embera NeuroTherapeutics
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metyrapone + oxazepam in cocaine use disorder (CUD) (3 arms), sponsored by Embera NeuroTherapeutics. Primary endpoints: Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity at 48 hours, Maximum Observed Concentration at 48 hours and 2 more. Started Mar 2018; status: completed.
02
Drugs
metyrapone + oxazepam
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT03404817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404817.